Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myelosuppression × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 9099 Neoplasms 6980 Carcinoma, Non-Small-Cell Lung 5112 Prostatic Neoplasms 4515 Colorectal Neoplasms 4087 Lung Neoplasms 3303 Leukemia, Myeloid, Acute 2752 Multiple Myeloma 2741 Neoplasm Metastasis 2737 Pancreatic Neoplasms 2551 Melanoma 2368 Lymphoma 2320 Ovarian Neoplasms 2300 Carcinoma, Hepatocellular 2207 Stomach Neoplasms 2084 Recurrence 1982 Head and Neck Neoplasms 1867 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1846 Lymphoma, Non-Hodgkin 1834 Leukemia 1824 Brain Neoplasms 1731 Glioblastoma 1620 Colonic Neoplasms 1592 Leukemia, Lymphocytic, Chronic, B-Cell 1569 Rectal Neoplasms 1534 Uterine Cervical Neoplasms 1475 Lymphoma, Follicular 1459 Squamous Cell Carcinoma of Head and Neck 1448 Lymphoma, Large B-Cell, Diffuse 1416 Carcinoma, Renal Cell 1391

Interventions

trilaciclib 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡